<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med</journal-id><journal-id journal-id-type="pmc-domain-id">463</journal-id><journal-id journal-id-type="pmc-domain">chimed</journal-id><journal-title-group><journal-title>Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">1749-8546</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11179363</article-id><article-id pub-id-type="pmcid-ver">PMC11179363.1</article-id><article-id pub-id-type="pmcaid">11179363</article-id><article-id pub-id-type="pmcaiid">11179363</article-id><article-id pub-id-type="pmid">38879549</article-id><article-id pub-id-type="doi">10.1186/s13020-024-00946-6</article-id><article-id pub-id-type="publisher-id">946</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>&#946;-elemene promotes microglial M2-like polarization against ischemic stroke via AKT/mTOR signaling axis-mediated autophagy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Q">Qiong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="L">Lu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="H">Hua</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yi</given-names></name><address><email>liyi20087598@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4150-3758</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="P">Ping</given-names></name><address><email>liping2004@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.254147.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9776 7793</institution-id><institution>State Key Laboratory of Natural Medicines, </institution><institution>China Pharmaceutical University, </institution></institution-wrap>#639 Longmian Dadao, Nanjing, 211198 China </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">452093</issue-id><elocation-id>86</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-17 09:25:15.523"><day>17</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13020_2024_Article_946.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Resident microglia- and peripheric macrophage-mediated neuroinflammation plays a predominant role in the occurrence and development of ischemic stroke. Microglia undergo polarization to M1/M2-like phenotype under stress stimulation, which mediates intracellular inflammatory response. &#946;-elemene is a natural sesquiterpene and possesses potent anti-inflammatory activity. This study aimed to investigate the anti-inflammatory efficacy and mechanism of &#946;-elemene in ischemic stroke from the perspective of balancing microglia M1/M2-like polarization.</p></sec><sec><title>Methods</title><p id="Par2">The middle cerebral artery occlusion (MCAO) model and photothrombotic stroke model were established to explore the regulation effect of &#946;-elemene on the cerebral ischemic injury. The LPS and IFN-&#947; stimulated BV-2 cells were used to demonstrate the anti-inflammatory effects and potential mechanism of &#946;-elemene regulating M1/M2-like polarization in vitro.</p></sec><sec><title>Results</title><p id="Par3">In C57BL/6&#160;J mice subjected to MCAO model and photothrombotic stroke model, &#946;-elemene attenuated neurological deficit, reduced the infarction volume and neuroinflammation, thus improving ischemic stroke injury. &#946;-elemene promoted the phenotype transformation of microglia from M1-like to M2-like, which prevented neurons from oxygen and glucose deprivation/reoxygenation&#160;(OGD/R) injury by inhibiting inflammatory factor release, thereby reducing neuronal apoptosis. Mechanically, &#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathway and increased AKT/mTOR mediated-autophagy, thereby promoting M2-like polarization&#160;of microglia.</p></sec><sec><title>Conclusions</title><p id="Par4">These results indicated that &#946;-elemene improved cerebral ischemic injury and promoted the transformation of microglia phenotype from M1-like to M2-like, at least in part, through AKT/mTOR-mediated autophagy. This study demonstrated that &#946;-elemene might serve as a promising drug for alleviating ischemic stroke injury.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13020-024-00946-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>&#946;-elemene</kwd><kwd>Ischemic stroke</kwd><kwd>M1/M2-like polarization</kwd><kwd>AKT/mTOR</kwd><kwd>Autophagy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81730104</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012226</institution-id><institution>Fundamental Research Funds for the Central Universities</institution></institution-wrap></funding-source><award-id>2632022ZD18</award-id><principal-award-recipient><name name-style="western"><surname>Li</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; International Society for Chinese Medicine and BioMed Central Ltd. 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Background</title><p id="Par30">Ischemic stroke takes up 80%&#8201;~&#8201;87% of total stroke cases, which represents the main factor inducing severe disability [<xref ref-type="bibr" rid="CR1">1</xref>]. The occurrence of ischemic stroke triggers a chain of malignant cascades, including excitotoxicity, oxidase stress, inflammation, and apoptosis, causing brain cell death and neurological function loss [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Currently, intravenous thrombolytic therapy is the most important measure to restore blood flow and improve ischemic stroke. Many drugs, including alteplase (rt-PA), urokinase, and teneplase, are commonly used in clinic. However, because of the narrow treatment window (t&#8201;&lt;&#8201;4.5&#160;h) and reperfusion injury, their clinical efficacy is limited [<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, there is a need to develop drugs alone or in combination with these drugs to expand therapeutic window in existing treatments, promote the therapeutic effect, and improve the prognosis of ischemic stroke.</p><p id="Par31">Neuroinflammation has become the focus of attention in ischemic stroke. It is activated immediately and persists for weeks or even months after ischemic stroke, which implies the predominant effect on cerebral ischemic injury [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The immune response is initiated once ischemic stroke occurs, which is achieved by damage-associated molecular patterns (DAMPs) in damaged neural cells for activating pattern recognition receptors in microglia. Subsequently, blood&#8211;brain barrier (BBB) collapses, causing peripheral immune cell activation and invasion. Notably, resident microglia and macrophages undergo a series of phenotypic changes depicted to be the functional dichotomy: classical (M1-like) as well as alternative (M2-like) activation [<xref ref-type="bibr" rid="CR7">7</xref>]. In the M1-like phenotype, microglia/macrophages secrete pro-inflammatory mediators like IL-6, IL-1&#946;, TNF-&#945;, chemokines, and iNOS, which can damage neurons [<xref ref-type="bibr" rid="CR8">8</xref>]. Under the M2-like phenotype, scavenger receptors and proangiogenic factors are expressed in microglia/macrophages, which is closely linked to neuroprotective effects. Microglial polarization is deemed to be crucial for the advancement of stroke. A switch of M1-like to M2-like phenotype of microglia blocks the mTOC1 pathway and improves stroke outcomes of middle cerebral artery occlusion (MCAO) mice [<xref ref-type="bibr" rid="CR9">9</xref>]. In line with this, pro-inflammatory M1-like macrophage polarization exacerbates ischemic stroke in mice [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, serum IL-6 and TNF-&#945; are abnormally elevated among stroke patients (&lt;&#8201;24&#160;h), and IL-6 level is positive correlation with stroke severity and poor outcomes [<xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, regulating the equilibration between M1-like and M2-like phenotype in microglia/macrophages may be an effective way to alleviate ischemic stroke injury.</p><p id="Par32">Autophagy is the primary mechanism mediating the transport of cellular contents to lysosomes for degradation and recycling, which is essential for maintaining cell homeostasis [<xref ref-type="bibr" rid="CR12">12</xref>]. It belongs to self-protection cellular process and can usually be activated by detrimental factors including ischemia and hypoxia [<xref ref-type="bibr" rid="CR13">13</xref>]. Numerous studies have confirmed that autophagy is closely associated with multiple diseases, such as cardiovascular diseases [<xref ref-type="bibr" rid="CR14">14</xref>], neurologic disorders [<xref ref-type="bibr" rid="CR15">15</xref>], and endocrine system disease [<xref ref-type="bibr" rid="CR16">16</xref>]. Activation of autophagy and Akt/CREB signaling&#160;pathway play a pivotal role in the neuroprotective effect of neonatal hypoxia&#8211;ischemia [<xref ref-type="bibr" rid="CR17">17</xref>]. In microglia derived from MCAO mice, the generation of autophagosome and the increased autophagy process significantly inhibit neuroinflammation against ischemic brain injury [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, accelerating the process of autophagy may be a potential strategy for treating ischemic stroke.</p><p id="Par33">As a sesquiterpene compound extracted from <italic toggle="yes">Curcuma wenyujin</italic>, &#946;-elemene exerts anti-tumor and anti-inflammatory biological activities. The chemical structure of &#946;-elemene is shown in Figure S1 of Additional file. Currently, &#946;-elemene has been clinically utilized as&#160;an anti-tumor agent because of the superb anti-cancer effect and low toxicity [<xref ref-type="bibr" rid="CR19">19</xref>]. Beyond the anti-tumor efficacy, &#946;-elemene also alleviates heart failure by blocking lipids-induced inflammation [<xref ref-type="bibr" rid="CR20">20</xref>], and inhibits cardiac inflammation via regulating JAK/STAT3-NF-&#954;B pathway [<xref ref-type="bibr" rid="CR21">21</xref>]. In sepsis-associated encephalopathy, &#946;-elemene blocks RAC1/MLK3/p38 pathway to decrease proinflammatory cytokines production [<xref ref-type="bibr" rid="CR22">22</xref>]. Although these studies verify that &#946;-elemene possesses significant anti-inflammatory activity, its efficacy and implying mechanism in ischemic stroke are still unclear. In our work, &#946;-elemene attenuated neurological deficit, reduced the infarction volume and neuroinflammation, thus improving ischemic stroke injury in C57BL/6&#160;J mice subjected to MCAO model and photothrombotic stroke model. Moreover, &#946;-elemene promoted the transformation of microglia from M1-like to M2-like phenotype in MCAO mice and LPS- and IFN-&#947;-induced BV-2 cells. Mechanically, &#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathway and increased AKT/mTOR mediated-autophagy, thereby promoting M2-like polarization&#160;of microglia. This study provides some proofs for applying &#946;-elemene in clinic for the treatment of ischemic stroke.</p></sec><sec id="Sec3"><title>Materials and methods</title><sec id="Sec4"><title>Reagents</title><p id="Par34">&#914;-elemene (purity: 99.40%, 100,268-201903) was obtained from National Institutes for Food and Drug Control (Shanghai, China). Cell Counting Kit-8&#160;(CCK-8) and BCA Protein Assay Kit were provided by Beyotime Biotechnology (Shanghai, China). LDH Assay Kit (CAT#A020-2-2) was bought from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). 3-Methyladenine (CAT#S2767) was from Selleck Chemicals LLC (Houston, TX, USA). SC79 (HY-18749) and miltefosine (HY-13685) were purchased from MedChemExpress (MCE) (Monmouth Junction, NJ, USA). Trizol (CAT#R401-01), HiScript Reverse Transcriptase (CAT#R122-01), and ChamQ SYBR Color qPCR Master Mix (CAT#Q411-02) were acquired from Vazyme Biotech (Nanjing, China). DL&#8209;3&#8209;n&#8209;butylphthalide (NBP) and edaravone were obtained from CSPC Pharmaceutical Co. Ltd. and China National Medicines Guorui Biomedical Technology Co., Ltd., respectively.&#160;Primary antibodies against &#946;-actin (1:1000, CAT#81,115-1-RR), mTOR (1:1000, CAT#66,888-1-Ig), p-P65 (Ser536) (IF: 1: 100, WB: 1:1000, CAT#82,335-1-RR), MyD88 (1:1000, CAT#23,230-1AP), LC3 (1:1000, CAT#14,600-1-AP), AKT (1:1000, CAT#60,203-2-Ig), p-AKT (Ser 473) (1:1000, CAT# 80,455-1-RR), AMPK (1:1000, CAT#10,929-2-AP), and NeuN (1:1000, CAT#26,975-1-AP) were provided by Proteintech (Chicago, IL, USA), whereas F4/80 (1:100, CAT#ab6640), P65 (1:1000, CAT#ab32536), Iba-1 (IF: 1:100, WB: 1:1000, CAT#ab178846), P62/SQSTM1 (1:1000, CAT#ab109012), p-AMPK (Thr 183&#8201;+&#8201;Thr 172) (1:1000, CAT#ab133448), and HIF-1&#945; (1:1000, CAT#ab179483) were from Abcam (Cambridge, MA, USA). Anti-TLR4 (IF: 1: 100, WB: 1:1000, CAT#sc-293072) and anti-p-mTOR (Ser2448) (1:1000, CAT# sc-293133) were bought from Santa Cruz (Shanghai, China). Anti-GFAP (1:1000, CAT#45,946), anti-Beclin-1 (1:1000, CAT#3495), ERK1/2 (1:1000, CAT#4695), p-ERK1/2 (1:1000, CAT#9101), p38 (1:1000, CAT#8690), p-P38 (1:1000, CAT#4511) were provided by Cell Signaling Technology (Danfoss, MA, USA). JNK (1:1000, CAT#AF6318) and p-JNK (1:1000, CAT#AF3318) were bought from Affinity Biosciences (Cincinnati, OH, USA). Mouse IL-1&#946; (CAT#EMC001b.96), IL-6 (CAT#EMC004.96), and TNF-&#945; (CAT#EMC102a.96) enzyme-linked immunosorbent assay (ELISA) kits were bought from NeoBioscience (Beijing, China). Neural Tissue Dissociation Kit (P) (CAT#130-092-628) was from Miltenyi Biotec (Bergisch Gladbach, Germany). PE-anti-F4/80 (CAT#12-4801-80) and PC5.5-anti-CD86 (CAT#15-0862-82) were obtained from Elabscience (Houston, TX, USA). Fixed Viability Stain 780 (CAT#565,388), PE-Cy7-anti-CD11b (CAT#552,850), FITC-anti-CD45 (CAT#553,079), mouse BD Fc Block (CAT#553,141), APC-anti-CD206 (CAT#141,708), and Annexin V-PE/7-AAD apoptosis assay kit (CAT#559,763) were from BD Pharmingen (San Diego, CA, USA). Recombinant Murine IL-4 (CAT#214-4), IL-13 (CAT#210-13) and IFN-&#947; (CAT#315-05) proteins were provided by PeproTech (Rocky Hill, NJ, USA). TTC (CAT#T8877) were provided by Sigma Chemical (St. Louis, MO, USA). Enhanced ECL Chemiluminescent Substrate Kit (CAT#36222ES76) was acquired from Yeasen Biotech (Shanghai, China). Dulbecco&#8217;s Modified Eagle&#8217;s Medium (DMEM, CAT# KGM12800-500) was purchased from KeyGen Biotech (Nanjing, China).</p></sec></sec><sec id="Sec5"><title>Cell culture and drug treatment in vitro</title><p id="Par35">BV-2 cells and HT-22 cells were obtained from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cells were cultivated in DMEM containing 10% FBS and 1% penicillin/streptomycin, and maintained in a sterile incubator containing 5% CO<sub>2</sub> at a constant temperature of 37&#160;&#8451;.</p><p id="Par36">To induce polarization of M1-like phenotype microglia, 100&#160;ng/mL LPS and 20&#160;ng/mL IFN-&#947; were co-cultured with BV-2 cells for 24&#160;h. To induce polarization of M2-like phenotype microglia, 20&#160;ng/mL IL-4 and 20&#160;ng/mL IL-13 were added to treat BV-2 cells for 24&#160;h. For the OGD/R model, HT-22 cells were incubated in glucose-free DMEM medium in an anaerobic container containing 1.5% O<sub>2</sub> for 4&#160;h. Thereafter, a standard culture medium was replaced and cultured in the normoxic incubator for another 12&#160;h.</p></sec><sec id="Sec6"><title>Cell viability</title><p id="Par37">Cells (1&#8201;&#215;&#8201;10<sup>6</sup>/mL) were inoculated into 96-well plates, and cultured with different concentrations of &#946;-elemene. After 24&#160;h, the cells were added to CCK8 solution (10&#160;&#956;L) for 30&#160;min. The microplate reader was then utilized for measuring absorbance at 450&#160;nm. Cell viability (%)&#8201;=&#8201;(OD<sub><italic toggle="yes">sample</italic></sub>&#8212;OD<sub><italic toggle="yes">blank</italic></sub>) / (OD<sub><italic toggle="yes">control</italic></sub>&#8212;OD<sub><italic toggle="yes">blank</italic></sub>)&#8201;&#215;&#8201;100%.</p></sec><sec id="Sec7"><title>Animals</title><p id="Par38">The 8&#8201;~ &#8201;10&#160;week-old male C57BL/6&#160;J mice (22&#8201;~&#8201; 24&#160;g) were offered by Model Animal Research Center (MARC) of Nanjing University (Nanjing, China). All animal care and experimental procedures gained approval from Animal Ethics Committee of China Pharmaceutical University (protocol code: 2021-12-006). Mice were fed under 22&#8201;&#177;&#8201;2&#160;&#8451;, 60% humidity, 12&#160;h/12&#160;h dark/light cycle conditions, and allowed to drink water and eat food freely.</p></sec><sec id="Sec8"><title>Construction of MCAO model</title><p id="Par39">The mice were anesthetized with isoflurane (3% induction and 1.5% maintenance) and immobilized in the supine position. Then, the left common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were exposed. An incision was made at the ECA and the silicone coated suture (1800A, Guangzhou jialing) was inserted, pushed to the ICA, and wedged in cerebral arterial circle for obstructing the origin of middle cerebral artery (MCA). Knot the CCA to stop blood flow. The mice were kept for 60&#160;min after occlusion and then the intraluminal filament was withdrawn. Sham control mice received identical anesthesia and artery exposure, except for the insertion of filament. The mice were kept under 37&#8201;&#177;&#8201;0.5&#160;&#176;C during the surgery and then returned to an individual cage when they recovered from anesthesia. The grouping and survival of mice during the experiment were summarized in Table S1 of the Additional file. After 24&#160;h, the mice were sacrificed under deep anesthesia for cervical dislocation, and then the brain tissue was collected for follow-up experiments.</p><p id="Par40">Animals were randomized as 7 groups: (i) Sham group that received 10% DMSO&#8201;+&#8201;90% corn oil (i.p.); (ii) model group receiving 10% DMSO&#8201;+&#8201;90% corn oil (i.p.); (iii) model group receiving 25&#160;mg/kg &#946;-elemene (i.p.); (iv) model group receiving 50&#160;mg/kg &#946;-elemene (i.p.); (v) model group receiving 100&#160;mg/kg &#946;-elemene (i.p.); (vi) model group receiving 50&#160;mg/kg NBP&#160;(i.g.); (vii) model group receiving 10&#160;mg/kg edaravone. According to the previous studies, mice were given 25, 50, 100&#160;mg/kg &#946;-elemene by intraperitoneal injection at 1&#160;h&#160;before ischemia and 5&#160;h&#160;after reperfusion, respectively [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The NBP group were given 50&#160;mg/kg NBP by intragastric administration at 10&#160;min and 5&#160;h after reperfusion, respectively [<xref ref-type="bibr" rid="CR24">24</xref>]. The edaravone group was intraperitoneally injected at a dose of 10&#160;mg/kg immediately after reperfusion [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par41">The neurological function was evaluated using the 5-level 4-point method of Zea-Longa. 0 suggested the absence of neurological impairment symptom; 1 suggested failure in full extension of left forepaw, mild nerve function injury; 2 suggested contralateral forelimb pronation, shoulder adduction, medium nerve function injury; 3 suggested turning and tipping to the opposite side, severe neurological impairment; 4 suggested inability to walk autonomously and partial loss of consciousness.</p></sec><sec id="Sec9"><title>Photothrombotic stroke model</title><p id="Par42">After anesthesia, mice were put into the stereotactic device (Wood Dale, IL, USA), followed by intraperitoneal injection of rose red (100&#160;mg/kg) for 5&#160;min. The skull was exposed through cutting the cortex, and the cold light source (11,500&#160;lx) was placed at the right side of the skull 1.5&#160;mm by a fiber bundle with a diameter of 2&#160;mm for 15&#160;min. The mice were kept under 37&#160;&#176;C to wake up. After the modeling, the mice were given &#946;-elemene continuously for 3&#160;days. The blood was collected, and then the mice were sacrificed to obtain brain tissue.</p><p id="Par43">Animals were randomized as 5 groups: (i) Sham group that received 10% DMSO&#8201;+&#8201;90% corn oil (i.p.); (ii) model group receiving 10% DMSO&#8201;+&#8201;90% corn oil (i.p.); (iii) model group receiving 25&#160;mg/kg &#946;-elemene (i.p.); (iv) model group receiving 50&#160;mg/kg &#946;-elemene (i.p.); (v) model group receiving 100&#160;mg/kg &#946;-elemene (i.p.).</p></sec><sec id="Sec10"><title>TTC staining</title><p id="Par44">The brain tissues were collected, prepared in 2&#160;mm coronal slices, and then immersed in 2% TTC for 15&#160;min and fixed in 4% paraformaldehyde overnight. The brain tissue sections were photographed and analyzed with Image J. The infarct ratio (%) was calculated by formula below: (contralateral hemispheric volume&#8212;ipsilateral hemispheric non-infarcted volume)/(contralateral hemispheric volume)&#8201;&#215;&#8201;100%.</p></sec><sec id="Sec11"><title>Reverse transcription-quantitative PCR (RT-qPCR)</title><p id="Par45">The brain tissue was extracted on ice with Trizol reagent. The total RNA was converted to cDNA by HiScript Reverse Transcriptase Kit. RT-PCR amplification was performed with ChamQ SYBR Color qPCR Master Mix under the conditions below: 30&#160;s under 95&#160;&#176;C; 10&#160;s under 95&#160;&#176;C, 30&#160;s under 60&#160;&#176;C for 45 cycles; 15&#160;s under 95&#160;&#176;C, and 1&#160;min under 60&#160;&#176;C. Relative mRNA levels were identified based on <italic toggle="yes">Actb</italic> and determined using 2<sup>&#8722;&#916;&#916;CT</sup> method. The primer sequences for target genes were shown in Additional file&#160;1: Table S2.</p></sec><sec id="Sec12"><title>Western-blotting analysis</title><p id="Par46">The brain tissue was added RIPA lysate containing protease/phosphatase inhibitors and homogenized on ice to extract total protein. The resultant lysate was subjected to 15&#160;min centrifugation (12 000&#160;rpm) under 4&#160;&#8451; to obtain supernatants. A BCA Protein Assay Kit was utilized for determining protein content. Proteins were separated by SDS-PAGE gel electrophoresis. Separated proteins were then electrophoretically transferred onto a nitrocellulose filter (NC) membrane, followed by 5% defatted milk for 2&#160;h under ambient temperature. Primary antibodies were added and incubated for overnight at 4&#160;&#8451;. After washing with TBST, the NC membranes were incubated with secondary antibody for 1&#160;h under ambient temperature. Enhanced chemoluminescence (Shanghai, China) was adopted for protein band visualization, and Image J software was utilized for quantification.</p></sec><sec id="Sec13"><title>Flow cytometry</title><p id="Par47">Neural Tissue Dissociation Kit was utilized to prepare single-cell brain tissue suspensions. The 30&#8211;70% Percoll gradient was applied for separating cells to obtain mononuclear cells. After washing with PBS, cell precipitation was resuspended by adding 100&#160;&#956;L PBS, followed by incubation with Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block) (2.4G2) at 4&#160;&#8451; for 20&#160;min to block nonspecific Fc receptor binding, and then labeling with Fixed Viability Stain 780, PE-Cy7-anti-CD11b, FITC-anti-CD45, PC5.5-anti-CD86, and APC-anti-CD206 on ice in dark for 20&#160;min. For BV-2 cell staining, Fixed Viability Stain 780, PE-anti-F4/80, PC5.5-anti-CD86, and APC-anti-CD206 were added to label cells. For detection the apoptosis level of HT-22 cells, Annexin V-PE/7-AAD apoptosis assay kit was used according to the specific protocols. Fluorescence was detected by Multicolor flow cytometry (CytoFLEX S). FlowJo software (FlowJo LLC, Ashland, OR, USA) was applied for result analysis.</p><sec id="Sec14"><title>ELISA</title><p id="Par48">Blood from sham and model mice was centrifugated at 3000&#160;rpm for 15&#160;min to separate serum. Cell culture media was acquired, followed by centrifugation at 3000&#160;rpm for 15&#160;min to collect the supernatant for subsequent analysis. Corresponding ELISA Kit was utilized to detect the levels of TNF-&#945;, IL-6, and IL-1&#946; following the protocols of the manufacturer.</p></sec></sec><sec id="Sec15"><title>Immunofluorescence</title><p id="Par49">The brain tissue of mice was processed by 4% paraformaldehyde fixation and paraffin embedding, and then cut into a thickness of 10&#160;&#956;m. The brain slices were dehydrated with ethanol, blocked with goat serum, followed by primary antibody incubation at 4&#160;&#8451; overnight, and secondary antibody incubation at room temperature. Images were obtained using laser confocal photography (Olympus FV3000).</p></sec><sec id="Sec16"><title>H&amp;E staining</title><p id="Par50">The heart, liver, and kidney tissues were subjected to 4% paraformaldehyde fixation, dehydration, paraffin embedding, and preparation into 10&#160;&#956;m sections for H&amp;E staining. An inverted microscope (OLYM-PUS, IXplore Standard, Tokyo, Japan) was adopted for image observation, and the Nikon DS-U3 software was applied in image capture.</p></sec><sec id="Sec17"><title>Conditioned media</title><p id="Par51">BV-2 cells were treated with 100&#160;ng/mL LPS and 20&#160;ng/mL IFN-&#947; for 24&#160;h. &#946;-elemene (40&#160;&#956;M or 80&#160;&#956;M) was incubated for 6&#160;h. Thereafter, freshly DMEM medium was replaced for 24&#160;h and obtained the supernatant as the CM.</p></sec><sec id="Sec18"><title>LDH analysis</title><p id="Par52">HT-22 cells were cultured into 96-well plates for OGD/R or CM treatment. The supernatant was collected to measure LDH level with an LDH Assay Kit.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p id="Par53">Results are represented by mean&#8201;&#177;&#8201;SEM (In vitro experiments: n&#8201;=&#8201;5, n represents independent experiments; In vivo experiments: n&#8201;&#8805;&#8201;5, n represents the number of mice). Statistical analysis was completed with Prism 8.0 software (GraphPad, San Diego, CA, USA). The data among multiple groups were compared using one-way ANOVA test followed by Tukey&#8217;s test. Each experiment was blinded and randomized for avoiding unwanted bias and generating equal-sized groups. For in vivo experiments, the mice with MCAO operation dying on the day and that did not reach the experimental endpoint were excluded from the analysis. <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 represented significant difference.</p></sec><sec id="Sec20"><title>Results</title><sec id="Sec21"><title>&#946;-elemene improved ischemic stroke in MCAO mice</title><p id="Par54">To evaluate the neuroprotection effect of &#946;-elemene on ischemic stroke, an MCAO mouse model was established. It has been reported that estrogen exerts protective effect on cerebral ischemia injury, so male C57BL/6&#160;J mice were chosen to establish the MCAO model [<xref ref-type="bibr" rid="CR26">26</xref>]. A schematic depicting of mouse modeling and sample collection was shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a. At first, the MCAO model was verified by monitoring cerebral blood flow (CBF) before MCAO, after MCAO, and after reperfusion (Additional file: Figure S2a). Compared with the sham group, the CBF of the MCAO group decreased by about 75% after ischemia and recovered to 60% after reperfusion, indicating successful ischemia/reperfusion surgery. As expected, MCAO operation led to significant neurological deficits and abnormally enlarged cerebral infarction volume, whereas &#946;-elemene reversed these alterations in MCAO mice (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b, c). NBP and edaravone are commonly used in the treatment of cerebral ischemia. As expected, they significantly improved neurological deficits and reduced infarct volume in MCAO mice. Next, we explored the regulatory effects of &#946;-elemene on neurons, microglia and astrocytes by detecting the characteristic markers NeuN, Iba-1 and GFAP expression, respectively. As shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>d, &#946;-elemene dose-dependently increased NeuN expression but decreased Iba-1 expression in the ischemic hemisphere of MCAO mice. In contrast, &#946;-elemene displayed less effect on the expression of GFAP, suggesting that it had beneficial effects on neurons and microglia. TUNEL staining showed that MCAO operation greatly increased the apoptosis of cells in peri-infarct area characterized by enhanced green fluorescence, while treatment with &#946;-elemene reversed this pathological change (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>e). In accordance with this, the NeuN staining assay on the hippocampus region showed that &#946;-elemene protected neurons from apoptosis after MCAO surgery (Additional file: Figure S2b). Meanwhile, a tendency towards the lower IL-6, TNF-&#945;, and IL-1&#946; levels was also observed within blood of mice after administration of &#946;-elemene (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>f). Hematoxylin&#8211;eosin Staining (H&amp;E) staining assay indicated that no marked pathological damage was observed in heart, liver, and kidney in MCAO mice (Additional file: Figure S2c). Meanwhile, we evaluated the neuroprotection effect of &#946;-elemene on the photothrombotic stroke model, and observed that &#946;-elemene increased cortex CBF and decreased cerebral infarct volume of model group (Additional file: Figure S3a-S3b). It also suppressed the expression of Iba-1 around cerebral infarction, along with the decreased IL-6 levels in peripheral blood (Additional file: Figure S3c-S3d). Collectively, these data suggested that &#946;-elemene ameliorated ischemic stroke injury.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>&#946;-elemene improved ischemic stroke in MCAO mice. <bold>a </bold>Schematic of experimental timeline; <bold>b</bold> Neurological deficit of mice was assessed using the 5-level 4-point method of Zea-Longa; <bold>c</bold> 2,3,5-triphenyltetrazolium chloride (TTC) -stained brain sections after MCAO model and quantification of total infarct volume, scale bar&#8201;=&#8201;5&#160;mm; <bold>d</bold> NeuN, Iba-1 and GFAP protein expression within ischemic hemisphere of MCAO mice; <bold>e</bold> TUNEL (green) staining on brain slices, scale bar&#8201;=&#8201;100&#160;&#956;m; <bold>f</bold> IL-6, TNF-&#945;, and IL-1&#946; levels within blood of MCAO mice. Results were indicated by means&#8201;&#177;&#8201;SEM (n&#8201;&#8805;&#8201;5, n represents the numbers of mice in each group). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p-</italic>values are analyzed using one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig1_HTML.jpg"/></fig></p></sec></sec><sec id="Sec22"><title>&#946;-elemene promoted the switch of microglia from&#160;M1-like to M2-like phenotype in MCAO mice</title><p id="Par55">The microglia inherent in the brain tissue and peripherally derived macrophages can be activated rapidly after ischemic stroke. Activated microglia exhibited morphological changes and polarized into M1-like or M2-like phenotypes. Thus, we determined the morphology of microglia in peri-infarct area using the confocal Z-stack projections. Microglial skeletal analysis indicated that not only the total length of microglial branches of MCAO mice decreased relative to the sham mice, but also the branch and terminal point numbers per cell were reduced, suggesting that microglia were activated. Whereas these morphological changes of microglia were rescued after &#946;-elemene treatment in MCAO mice (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a, b). Consistently, pro-inflammatory microglia (CD86<sup>+</sup>CD206<sup>&#8722;</sup>) were significantly increased after MCAO operation by flow cytometry analysis. After administration of &#946;-elemene, the proportion of the M1-like phenotype (CD86<sup>+</sup>CD206<sup>&#8722;</sup>) decreased while the M2-like phenotype (CD206<sup>+</sup>CD86<sup>&#8722;</sup>) increased (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>c, d). Meanwhile, &#946;-elemene greatly down-regulated M1-like phenotype-associated genes <italic toggle="yes">Il6, Il1b</italic>, and <italic toggle="yes">Nos2</italic> mRNA expression while up-regulated M2-like phenotype-associated genes <italic toggle="yes">Arg1</italic>, <italic toggle="yes">Mrc1</italic>, and <italic toggle="yes">Il10</italic> mRNA expression in the ischemic hemisphere of MCAO mice (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>e, f). The above results collectively demonstrated that &#946;-elemene repressed the neuroinflammation through promoting the switch of M1-like to M2-like phenotype microglia in MCAO mice.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>&#946;-elemene promoted the transformation of microglia from M1-like to M2-like phenotype in MCAO mice. <bold>a</bold> Typical image showing Iba-1 expression and Z-stack projection for microglia within peri-infarct in ischemic hemisphere, scale bar&#8201;=&#8201;10&#160;&#956;m; <bold>b</bold> microglial skeletal analysis on total length, branch point and terminal point numbers in MCAO mice; <bold>c </bold>gating strategy used to identify infiltrating and resident microglia after MCAO model; <bold>d</bold> proportions of M1-like and M2-like phenotype microglia in the ischemic hemisphere; <bold>e</bold><bold>, </bold><bold>f</bold> M1-like and M2-like phenotype-associated genes levels in the ischemic hemisphere. Results were represented by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values were analyzed using one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec23"><title>&#946;-elemene promoted microglia M2 polarization in vitro</title><p id="Par56">Subsequently, the microglia polarization model in vitro was established to investigate the role of &#946;-elemene in regulating M1/M2-like paradigm. BV-2 cell is a type of microglia derived from mice, which retains microglia morphological and functional characteristics and is widely used in neuroscience research. The CCK-8 results confirmed the toxicity of &#946;-elemene to BV-2 cells at high-dose (&gt;&#8201;160&#160;&#956;M) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a). Therefore, we chose a lower dose for following study. F4/80 is cell surface glycoprotein, which has been widely used as unique marker of murine microglia/macrophages. Cells were treated with IL-4 and IL-13 for promoting the production of anti-inflammatory factors and driving microglia to M2 polarization (F4/80<sup>+</sup>/CD206<sup>+</sup>). As revealed by flow cytometry analysis, IL-4 and IL-13 stimulation significantly increased M2 polarization of microglia, and &#946;-elemene treatment exerted few influences on this result (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b, c). Correspondingly, &#946;-elemene also did not alter M2-like phenotype-associated genes <italic toggle="yes">Arg1</italic>, <italic toggle="yes">Mrc1</italic>, and <italic toggle="yes">Il10</italic> expression upon IL-4 and IL-13 induction (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>d). However, CD86<sup>+</sup>CD206<sup>&#8722;</sup> (M1-like phenotype) microglial proportion dose-dependently declined, and CD206<sup>+</sup>CD86<sup>&#8722;</sup> (M2-like phenotype) microglia proportion increased in LPS- and IFN-&#947;-mediated BV-2 cells after &#946;-elemene treatment, which showed the role of &#946;-elemene in promoting the transformation of microglia from M1-like to M2-like phenotype (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>e). In support, &#946;-elemene significantly decreased M1-like associated gene levels but increased M2-like associated-gene expression in LPS-and IFN-&#947;-mediated BV-2 cells (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>f, g). Taken together, &#946;-elemene promoted the transformation of microglia from M1-like to M2-like phenotype for correcting the imbalance between these two phenotypes.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>&#946;-elemene promoted microglial M2-like polarization in vitro. <bold>a</bold> The BV-2 cell viability was determined with &#946;-elemene at indicated doses for 24&#160;h; <bold>b&#8211;d</bold> &#946;-elemene (40, 80&#160;&#956;M) was added to BV-2 cells with 20&#160;ng/mL IL-4 and 20&#160;ng/mL IL-13 for 24&#160;h. Typical image showing M2-like microglial proportion (<bold>b, c</bold>) and M2-like phenotype-associated gene levels (<bold>d</bold>); <bold>e&#8211;g</bold> BV-2 cells were incubated with &#946;-elemene (40, 80&#160;&#956;M) when exposed to 100&#160;ng/mL LPS and 20&#160;ng/mL IFN-&#947; for 24&#160;h. (<bold>e</bold>) Typical image showing M1/M2-like microglial proportion; <bold>f, g</bold> M1-like and M2-like phenotype-associated genes levels were analyzed. Results were represented by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values were analyzed through one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec24"><title>&#946;-elemene exerted neuroprotective function by inhibiting the activation of microglia</title><p id="Par57">Sequentially, we investigated the role of &#946;-elemene in regulating neurons, and a neuronal damage model based on OGD/R was established. HT-22 cell is a mouse hippocampal neuron cell line derived from HT4 cell line, which is a valuable model for studies of function of neuronal cells in vitro. Interestingly, treatment with &#946;-elemene (40&#160;&#956;M, 80&#160;&#956;M) could not mitigate the damage on HT-22 cells caused by OGD/R (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a, b). Furthermore, we examined the mRNA levels of antioxidant-associated genes (<italic toggle="yes">Sod2</italic>, <italic toggle="yes">Nqo1</italic>, <italic toggle="yes">Hmox1</italic>, and <italic toggle="yes">Cat</italic>) in HT-22 cells and discovered that &#946;-elemene made no difference to the expression levels of these genes (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>c). These results confirmed that &#946;-elemene could not exert protective effects on neurons directly. Therefore, it was speculated that neuroprotective effect of &#946;-elemene was probably associated with the polarization of M1/M2-like phenotype microglia. We collected the supernatant of LPS-and IFN-&#947;-treated BV-2 cells as CM to stimulate HT-22 cells. As shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>d, e, &#946;-elemene-treated CM remarkably increased the viability of HT-22 cell and reduced the release of Lactate Dehydrogenase (LDH). Consistently, the mRNA levels of antioxidant-associated genes (<italic toggle="yes">Sod2</italic>, <italic toggle="yes">Nqo1</italic>, <italic toggle="yes">Hmox1</italic>, and <italic toggle="yes">Cat</italic>) in HT-22 cells were significantly increased after &#946;-elemene-treated CM treatment (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>f). Flow cytometry analysis also found that the apoptosis ratio of neurons was reduced with the &#946;-elemene-treated CM treatment (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>g). These data revealed that &#946;-elemene exerted indirect neuroprotective function by inhibiting the activation of inflammatory M1-like phenotype microglia.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>&#946;-elemene exerted neuroprotective function by inhibiting the activation of microglia. <bold>a</bold> HT-22 cell viability was determined with OGD 4&#160;h/R12 h stimulation; <bold>b</bold> the supernatant from HT-22 cells was obtained and LDH levels were assessed; <bold>c</bold> the mRNA of antioxidant-associated genes was detected in OGD/R-mediated HT-22 cells; <bold>d&#8211;g</bold> supernatant from BV-2 cells as a CM to stimulate HT-22 cells. The viability of HT-22 cells (<bold>d</bold>), the release of LDH (<bold>e</bold>), the mRNA of antioxidant-associated genes (<bold>f</bold>), and the apoptosis of HT-22 cells were analyzed (<bold>g</bold>). Results were represented by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values were analyzed through one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec25"><title>&#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathways in microglia</title><p id="Par58">It has been reported that TLR4/NF-&#954;&#914; and MAPK signaling pathways were activated in M1-like phenotype microglia [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Thus, we first explored the regulation of &#946;-elemene on TLR4/NF-&#954;&#914; signaling pathway. As expected, &#946;-elemene prevented the expression of TLR4 and MyD88, and reduced P65 phosphorylation in LPS-and IFN-&#947;-treated BV-2 cells (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a). Consequently, &#946;-elemene dramatically reduced the IL-6 production at the concentrations of 40&#160;&#956;M and 80&#160;&#956;M (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>b). In line with this, immunofluorescence staining observed the strong activation of F4/80-positive microglia/macrophages, and up-regulated the expression of TLR4 and p-P65 in the peri-infarct area of the MCAO mice, whereas &#946;-elemene treatment observably attenuated the activation of TLR4/NF-&#954;&#914; signaling pathway (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>c, d). In addition, we also investigated the effects of &#946;-elemene on MAPK signalling&#160;pathway, including the expression of p-ERK1/2/ERK1/2, p-JNK/JNK and p-P38/P38. The results showed that &#946;-elemene significantly inhibited the phosphorylation of ERK1/2, JNK and P38, which indicated the inhibitory effect on MAPK pathway activation (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>e). These results supported that &#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathways in M1-like phenotype microglia.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>&#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signalling&#160;pathways in microglia. <bold>a</bold> TLR4, MyD88, p-P65, and P65 protein levels in LPS- and IFN-&#947;-treated BV-2 cells; <bold>b</bold> the level of IL-6 in LPS- and IFN-&#947;-treated BV-2 cells; <bold>c, d</bold> TLR4 and p-P65 protein levels within microglia in the peri-infarct area of the MCAO mice, scale bar&#8201;=&#8201;50&#160;&#956;m. <bold>e</bold> p-ERK1/2/ERK1/2, p-JNK/JNK and p-P38/P38 protein levels in LPS- and IFN-&#947;-treated BV-2 cells; Results were indicated by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values are analyzed through one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec26"><title>&#946;-elemene promoted autophagy to enhance microglia M2-like polarization</title><p id="Par59">Thereafter, we would like to explore the other potential mechanism of &#946;-elemene in regulating M1-like to M2-like phenotypic transformation of microglia. It has been reported that macrophages undergo the Warburg effect manifested as enhanced glycolysis when they are polarized into the M1-like phenotype. Therefore, we examined the mRNA expression of the metabolic enzymes related to glycolysis (<italic toggle="yes">Hk2, Pkm, Ldha)</italic>. As shown in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>a, &#946;-elemene did not affect the mRNA levels of these genes in LPS-and IFN-&#947;-induced BV-2 cells, suggesting that the effect of &#946;-elemene on microglia was in a glycolysis-independent manner. It has been reported that autophagy can regulate the polarization of macrophages [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, we used DALGreen fluorescent dye to label the autophagy level in BV-2 cells. As shown in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>b, LPS- and IFN-&#947; stimulation decreased green fluorescence of DALGreen fluorescent dye, whereas &#946;-elemene treatment showed increased green fluorescence, indicating enhanced autophagy. Meanwhile, LPS-and IFN-&#947; stimulation decreased the expression of autophagy-related protein Beclin-1 and LC3-II but increased p62/SQSTM1 expression, whereas these alterations were significantly reversed by &#946;-elemene treatment. And the treatment of 3-MA (an autophagy inhibitor) significantly abolished the regulation of &#946;-elemene on autophagy-associated protein expression (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>c). Then, we further clarify the relationship between autophagy and microglial polarization. As shown in Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>d, compared with the control group, 3-MA alone had no effect on M1/M2-like polarization of microglia, while the addition of 3-MA increased the M1-like polarization ratio and reduced the M2-like polarization ratio of BV-2 cells under the condition of LPS and IFN-&#947; insult. &#946;-elemene enhanced the transformation of BV-2 cells from M1-like to M2-like phenotype, which was abrogated with 3-MA administration (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>d). Similarly, the increased levels of M2-like phenotype-associated genes whereas decreased levels of M1-like associated genes by &#946;-elemene were also revoked by 3-MA supplementation in LPS-and IFN-&#947;-treated BV-2 cells (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>e, f). These results collectively demonstrated that &#946;-elemene promoted microglial M2-like polarization by promoting autophagy.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>&#946;-elemene promoted autophagy to enhance M2-like polarization of microglia. <bold>a</bold> The mRNA expression of the metabolic enzymes-related to glycolysis (<italic toggle="yes">Hk2, Pkm, Ldha</italic>) was examined in LPS- and IFN-&#947;-induced BV-2 cells; <bold>b</bold> autolysosomes were labled by DALGreen fluorescent dye in LPS- and IFN-&#947;-induced BV-2 cells, scale bar&#8201;=&#8201;10&#160;&#956;m; <bold>c</bold> beclin-1, p62/SQSTM1, and LC3-II protein levels in LPS- and IFN-&#947;-induced BV-2 cells with indicated reagents; <bold>d</bold> M1/M2-like microglial proportion was analyzed in BV-2 cells by flow cytometry when treated with 3-MA; <bold>e</bold><bold>, </bold><bold>f</bold> M1/M2-like phenotype-associated gene levels. Data were represented by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values were analyzed using one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec27"><title>&#946;-elemene prevented the activation of AKT/mTOR signaling pathway to promote autophagy</title><p id="Par60">Several literatures have revealed that the upstream pathway regulating autophagy is mainly involved in HIF-1&#945;/mTOR, AMPK/mTOR, and AKT/mTOR in macrophages [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. We firstly detected the phosphorylation of mTOR and found that &#946;-elemene treatment significantly prevented the expression of p-mTOR/mTOR in LPS-and IFN-&#947;-induced BV-2 cells (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>a). Then, we determined the protein levels of HIF1&#945;, p-AMPK/AMPK and p-AKT/AKT in LPS- and IFN-&#947;-induced BV-2 cells, and found that &#946;-elemene significantly down-regulated the expression of p-AKT/AKT (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>b) but scarcely affected HIF-1&#945; and p-AMPK/AMPK (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>c, d). In line with the results of in vitro studies, &#946;-elemene also decreased the protein levels of p-AKT and p-mTOR in peri-infarct area of MCAO mice (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>e, f). To further confirm the effect of &#946;-elemene on microglial autophagy by regulating AKT/mTOR signaling pathway, we used SC79 (AKT activator) and miltefosine (AKT inhibitor) to detect the expression of p-mTOR/mTOR and autophagy-related protein, and found that &#946;-elemene-downregulated p-AKT/AKT and p-mTOR/TOR were significantly up-regulated under the action of SC79 in LPS- and IFN-&#947;-induced BV-2 cells (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>g). Similarly, increased Beclin-1 and LC3-II protein levels but reduced p62/SQSTM1 protein level of &#946;-elemene were also significantly reversed by SC79 treatment (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>h). Subsequently, the increased mRNA levels of M2-like phenotype-associated genes but decreased mRNA levels of M1-like phenotype-associated genes by &#946;-elemene were also revoked by SC79 supplementation in LPS-and IFN-&#947;-treated BV-2 cells (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>i). Miltefosine (AKT inhibitor) showed similar regulatory effects as &#946;-elemene, further confirming the efficacy of &#946;-elemene on autophagy by inhibiting AKT (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>g-7i). Collectively, these results revealed that &#946;-elemene enhanced the switch of microglia from M1-like to M2-like phenotype, at least partially, through AKT/mTOR-mediated autophagy.<fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>&#946;-elemene activated autophagy through preventing the activation of AKT/mTOR signaling pathway. <bold>a-d</bold> p-mTOR/mTOR, p-AKT/AKT, HIF-1&#945; and p-AMPK/AMPK protein levels were determined in LPS- and IFN-&#947;-induced BV-2 cells; <bold>e</bold><bold>, </bold><bold>f </bold>p-mTOR and p-AKT protein levels within microglia in the peri-infarct area of MCAO mice, scale bar&#8201;=&#8201;20&#160;&#956;m. <bold>g, h</bold> p-AKT/AKT, p-mTOR/mTOR, Beclin-1, p62/SQSTM1, and LC3-II protein levels in LPS- and IFN-&#947;-induced BV-2 cells with indicated reagents; <bold>i</bold> M1/M2-like phenotype-associated gene levels; Results were indicated by means&#8201;&#177;&#8201;SEM (n&#8201;=&#8201;5). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <italic toggle="yes">p</italic>-values are analyzed through one-way ANOVA followed by Tukey&#8217;s test. ns, no significant difference</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="13020_2024_946_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec28"><title>Discussion</title><p id="Par61">Currently, ischemic stroke is mainly treated with thrombolytic therapy and endovascular intervention, but these treatments often cause reperfusion injury [<xref ref-type="bibr" rid="CR34">34</xref>]. Consequently, there is a high need to develop neuroprotective therapeutic strategies for combating reperfusion injury. Accumulating evidence emphasizes that post-ischemic inflammation has an enormous impact on various cerebral ischemic injury stages [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Anti-inflammatory strategies are attractive in ischemic stroke therapy on account of their wide therapeutic window compared with the currently mainstream reperfusion-based treatments.</p><p id="Par62">As the multi-functional medicine, <italic toggle="yes">Curcuma wenyujin</italic> possesses beneficial activities of enhancing blood circulation and dredging the meridians, which is adopted for treating different disorders. Over the past years, 169 compounds have been discovered from <italic toggle="yes">Curcuma wenyujin</italic> [<xref ref-type="bibr" rid="CR37">37</xref>]. Among them, &#946;-elemene as a volatile component can readily penetrate the BBB and has been explored extensively for treating brain cerebropathy [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The pharmacokinetic study indicates that &#946;-elemene distributes rapidly to the brain and the elimination is slower than in other tissues when it&#160;is intravenously administrated in rats [<xref ref-type="bibr" rid="CR40">40</xref>]. Consequently, we investigated the effect of &#946;-elemene on ischemic stroke injury and found that it attenuated neurological deficit, reduced the infarction volume and neuroinflammation, thus improving ischemic stroke injury in C57BL/6&#160;J mice subjected to MCAO model and photothrombotic stroke model.</p><p id="Par63">&#946;-elemene has been explored extensively because of the extensive pharmacological effects including anti-inflammation and anti-cancer. &#946;-elemene inactivates the miR-1323/Cbl-b/EGFR pathway to prevent the metastasis of multidrug-resistant gastric cancer cells [<xref ref-type="bibr" rid="CR41">41</xref>]. In non-small cell lung cancer, &#946;-elemene induces ferroptosis, resulting in the increased sensitivity of erlotinib [<xref ref-type="bibr" rid="CR42">42</xref>]. Combination therapy with &#946;-elemene and cetuximab remarkably inhibits the growth of colorectal cancer cells [<xref ref-type="bibr" rid="CR43">43</xref>]. Additionally, &#946;-elemene is also demonstrated with anti-inflammatory effect. It efficiently combats obesity-related chronic inflammation through promoting Tregs production in mice intestinal immune system [<xref ref-type="bibr" rid="CR44">44</xref>]. &#946;-elemene attenuates lipid-induced inflammation by down-regulating IL-6 expression in vitro [<xref ref-type="bibr" rid="CR20">20</xref>]. Consistent with these studies, our work found that &#946;-elemene decreased the mRNA levels of pro-inflammatory genes and increased the mRNA levels of anti-inflammatory genes in LPS- and IFN-&#947;-induced BV-2 cells.</p><p id="Par64">Microglia are one of the first immune cell populations to react to danger signals in the central nervous system (CNS). Within minutes after ischemic stroke, microglia are activated in an M1-like phenotype and release pro-inflammatory mediators, such as IL-6, TNF-&#945;, iNOS, ROS, leading to the break of the BBB [<xref ref-type="bibr" rid="CR45">45</xref>]. On the contrary, activated M2-like microglia produce anti-inflammatory cytokine like IL-10, arginase 1, trophic or growth factors [<xref ref-type="bibr" rid="CR46">46</xref>]. In spite of the dichotomy between M1/M2 polarization of microglia is a simplistic conceptual framework, it remains to be useful for enhancing our understanding of the functional status of microglia in period of injury advancement and helping us to develop novel therapy [<xref ref-type="bibr" rid="CR47">47</xref>]. Compelling evidence has implicated that the imbalance between M1-like and M2-like microglia is responsible for the inflammation in ischemic stroke-related pathogenic mechanism [<xref ref-type="bibr" rid="CR8">8</xref>]. Targeting microglial polarization is considered a promising therapeutic strategy for neuroinflammation. &#946;-elemene improves M1/M2-like tumor-associated macrophage proportion and evokes a robust tumor immune response [<xref ref-type="bibr" rid="CR48">48</xref>]. &#946;-elemene also modulates M1-like and M2-like polarization through inhibiting MAPK signaling pathway in macrophage dysfunction resulting from high-fat diet (HFD) [<xref ref-type="bibr" rid="CR28">28</xref>]. In our study, &#946;-elemene favorably inactivated microglia, as evidenced by lowered Iba-1 expression, elevated branch and ending numbers per microglia. Moreover, we found that &#946;-elemene promoted microglial polarization from M1-like to M2-like phenotype within MCAO mice and LPS- and IFN-&#947;-treated BV-2 cells. Furthermore, &#946;-elemene protected neurons against OGD/R injury by inhibiting macrophages inflammatory factor release, thereby reducing neuronal apoptosis.</p><p id="Par65">In our work, &#946;-elemene significantly inhibited the TLR4/NF-&#954;B and MAPK signaling pathways, which were consistent with previous reports [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. It has been shown that &#946;-elemene can promote cell-protective autophagy during malignancy. In leukemia THP-1 cells, &#946;-elemene promotes dissociation of Bcl-2/Beclin-1 complex, leading to autophagosome generation and cell autophagy [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, microglial autophagy has found to prevent neuronal damage by facilitating the microglial M2 polarization and decreasing its mediated inflammatory response. Enhanced autophagy inhibits NLRP3 inflammasome expression and decreases inflammatory response [<xref ref-type="bibr" rid="CR51">51</xref>]. Inversely, autophagy inhibitor 3-MA pretreatment obviously promotes microglial activation [<xref ref-type="bibr" rid="CR52">52</xref>]. In our study, &#946;-elemene promoted microglial M2-like polarization both in MCAO mice and BV-2 cells. Mechanically, &#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathways and increased AKT/mTOR mediated-autophagy to promote microglia M2-like polarization.</p><p id="Par66">Although previous researches have disclosed the anti-inflammatory effects of &#946;-elemene, its efficacy and detailed mechanism in ischemic stroke are less reported. Our study indicated that &#946;-elemene attenuated neurological deficit, reduced the infarction volume, and promoted the switch of microglia from M1-like to M2-like phenotype, thus improving ischemic stroke injury. Mechanically, &#946;-elemene prevented the activation of TLR4/NF-&#954;&#914; and MAPK signaling pathways, and increased AKT/mTOR mediated-autophagy to promote microglia M2-like polarization. This study provides insight into the potential mechanism of &#946;-elemene to be a potent agent for treating ischemic stroke injury. However, this research only demonstrated the potency of &#946;-elemene in laboratory animal model, and further experiments remain to be needed to investigate whether &#946;-elemene can be used in clinic for treating ischemic stroke injury.</p></sec><sec id="Sec29"><title>Conclusions</title><p id="Par67">This study demonstrated the feasibility of &#946;-elemene as a brain protection agent for treating cerebral ischemic injury. &#946;-elemene attenuated neurological deficit, reduced the infarction volume and enhanced microglial M2 polarization in MCAO mice. Mechanically, &#946;-elemene prevented TLR4/NF-&#954;&#914; and MAPK signaling pathway, and promoted AKT/mTOR-mediated autophagy to enhance the switch of microglia from M1-like to M2-like phenotype, thereby inhibiting inflammatory factor production to protect neurons from apoptosis. Our study implies the pharmacological action and potential mechanism of &#946;-elemene in alleviating ischemic stroke injury, which provides some ideas for expanding the clinical application of &#946;-elemene.</p></sec><sec sec-type="supplementary-material"><sec id="Sec30"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13020_2024_946_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Additional file 1. </p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BBB</term><def><p id="Par5">Blood&#8211;brain barrier</p></def></def-item><def-item><term>BSA</term><def><p id="Par6">Bovine serum albumin</p></def></def-item><def-item><term>CCA</term><def><p id="Par7">Common carotid artery</p></def></def-item><def-item><term>CM</term><def><p id="Par8">Conditioned media</p></def></def-item><def-item><term>CNS</term><def><p id="Par9">Central nervous system</p></def></def-item><def-item><term>CCK8</term><def><p id="Par10">Cell Counting Kit-8</p></def></def-item><def-item><term>NBP</term><def><p id="Par11">DL&#8209;3&#8209;n&#8209;butylphthalide</p></def></def-item><def-item><term>DAMPs</term><def><p id="Par12">Damage-associated molecular patterns</p></def></def-item><def-item><term>DMEM</term><def><p id="Par13">Dulbecco&#8217;s modified eagle medium</p></def></def-item><def-item><term>ELISA</term><def><p id="Par14">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>ECA</term><def><p id="Par15">External carotid artery</p></def></def-item><def-item><term>Edaravone</term><def><p id="Par16">3&#8209;Methyl&#8209;1&#8209;phenyl&#8209;2&#8209;pyrazolin&#8209;5&#8209;one</p></def></def-item><def-item><term>FBS</term><def><p id="Par17">Fetal bovine serum</p></def></def-item><def-item><term>H&amp;E</term><def><p id="Par18">Hematoxylin and eosin</p></def></def-item><def-item><term>IL-6</term><def><p id="Par19">Interleukin-6</p></def></def-item><def-item><term>IL-1&#946;</term><def><p id="Par20">Interleukin-1&#946;</p></def></def-item><def-item><term>ICA</term><def><p id="Par21">Internal carotid artery</p></def></def-item><def-item><term>iNOS</term><def><p id="Par22">Inducible nitric oxide synthase</p></def></def-item><def-item><term>LDH</term><def><p id="Par23">Lactate dehydrogenase</p></def></def-item><def-item><term>MCAO</term><def><p id="Par24">Middle cerebral artery occlusion</p></def></def-item><def-item><term>MCA</term><def><p id="Par25">Middle cerebral artery</p></def></def-item><def-item><term>NF-&#954;B</term><def><p id="Par26">Nuclear factor kappa-B</p></def></def-item><def-item><term>OGD/R</term><def><p id="Par27">Oxygen and glucose deprivation/reoxygenation</p></def></def-item><def-item><term>tPA</term><def><p id="Par28">Tissue plasminogen activator</p></def></def-item><def-item><term>TNF-&#945;</term><def><p id="Par29">Tumor necrosis factor-&#945;</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>All authors thank Ping Zhou, Yumeng Shen, and Li Guo from the State Key Laboratory of Natural Medicines of China Pharmaceutical University&#160;for technical support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>QZ: Methodology, Data curation, Writing-original draft. LC: methodology, Software. XZ: formal analysis, Validation. HY: investigation. YL: data curation, Funding acquisition, Writing-review &amp; editing. PL: conceptualization, Funding acquisition, Project administration, Supervision.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work is supported by the National Natural Science Foundation of China (No.81730104) and the Fundamental Research Funds for the Central Universities (No. 2632022ZD18).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data produced from this study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par68">All animal care and experimental procedures gained approval from Animal Ethics Committee of China Pharmaceutical University (protocol code: 2021-12-006).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par69">All authors consent to publish this manuscript.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miao</surname><given-names>C-y</given-names></name></person-group><article-title>Angiogenesis after ischemic stroke</article-title><source>Acta Pharmacol Sin</source><year>2023</year><volume>44</volume><issue>7</issue><fpage>1305</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1038/s41401-023-01061-2</pub-id><pub-id pub-id-type="pmid">36829053</pub-id><pub-id pub-id-type="pmcid">PMC10310733</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekerdag</surname><given-names>E</given-names></name><name name-style="western"><surname>Solaroglu</surname><given-names>I</given-names></name><name name-style="western"><surname>Gursoy-Ozdemir</surname><given-names>Y</given-names></name></person-group><article-title>Cell death mechanisms in stroke and novel molecular and cellular treatment options</article-title><source>Curr Neuropharmacol</source><year>2018</year><volume>16</volume><issue>9</issue><fpage>1396</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.2174/1570159X16666180302115544</pub-id><pub-id pub-id-type="pmid">29512465</pub-id><pub-id pub-id-type="pmcid">PMC6251049</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambertsen</surname><given-names>KL</given-names></name><name name-style="western"><surname>Finsen</surname><given-names>B</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>BH</given-names></name></person-group><article-title>Post-stroke inflammation-target or tool for therapy?</article-title><source>Acta Neuropathol</source><year>2019</year><volume>137</volume><issue>5</issue><fpage>693</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1930-z</pub-id><pub-id pub-id-type="pmid">30483945</pub-id><pub-id pub-id-type="pmcid">PMC6482288</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanderson</surname><given-names>TH</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Przyklenk</surname><given-names>K</given-names></name><name name-style="western"><surname>H&#252;ttemann</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation</article-title><source>Mol Neurobiol</source><year>2013</year><volume>47</volume><issue>1</issue><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s12035-012-8344-z</pub-id><pub-id pub-id-type="pmid">23011809</pub-id><pub-id pub-id-type="pmcid">PMC3725766</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>J</given-names></name><name name-style="western"><surname>Lyden</surname><given-names>PD</given-names></name></person-group><article-title>Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema</article-title><source>Int J Stroke</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/ijs.12434</pub-id><pub-id pub-id-type="pmid">25598025</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name><name name-style="western"><surname>Anrather</surname><given-names>J</given-names></name></person-group><article-title>The immunology of stroke: from mechanisms to translation</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><issue>7</issue><fpage>796</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/nm.2399</pub-id><pub-id pub-id-type="pmid">21738161</pub-id><pub-id pub-id-type="pmcid">PMC3137275</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Won</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JK</given-names></name><name name-style="western"><surname>Stein</surname><given-names>DG</given-names></name></person-group><article-title>Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats</article-title><source>Brain Behav Immun</source><year>2015</year><volume>49</volume><fpage>267</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2015.06.007</pub-id><pub-id pub-id-type="pmid">26093305</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subedi</surname><given-names>L</given-names></name><name name-style="western"><surname>Gaire</surname><given-names>BP</given-names></name></person-group><article-title>Phytochemicals as regulators of microglia/macrophages activation in cerebral ischemia</article-title><source>Pharmacol Res</source><year>2021</year><volume>165</volume><fpage>105419</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105419</pub-id><pub-id pub-id-type="pmid">33450385</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type</article-title><source>Faseb j</source><year>2016</year><volume>30</volume><issue>10</issue><fpage>3388</fpage><lpage>3399</lpage><pub-id pub-id-type="doi">10.1096/fj.201600495R</pub-id><pub-id pub-id-type="pmid">27342766</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sult2b1 deficiency exacerbates ischemic stroke by promoting pro-inflammatory macrophage polarization in mice</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>20</issue><fpage>10074</fpage><lpage>10090</lpage><pub-id pub-id-type="doi">10.7150/thno.61646</pub-id><pub-id pub-id-type="pmid">34815805</pub-id><pub-id pub-id-type="pmcid">PMC8581421</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anrather</surname><given-names>J</given-names></name><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name></person-group><article-title>Inflammation and stroke: an overview</article-title><source>Neurotherapeutics</source><year>2016</year><volume>13</volume><issue>4</issue><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s13311-016-0483-x</pub-id><pub-id pub-id-type="pmid">27730544</pub-id><pub-id pub-id-type="pmcid">PMC5081118</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>RQ</given-names></name><name name-style="western"><surname>Ren</surname><given-names>C</given-names></name><name name-style="western"><surname>Xia</surname><given-names>ZF</given-names></name><name name-style="western"><surname>Yao</surname><given-names>YM</given-names></name></person-group><article-title>Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles</article-title><source>Autophagy</source><year>2021</year><volume>17</volume><issue>2</issue><fpage>385</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1080/15548627.2020.1725377</pub-id><pub-id pub-id-type="pmid">32048886</pub-id><pub-id pub-id-type="pmcid">PMC8007140</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Shao</surname><given-names>B-Z</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miao</surname><given-names>C-Y</given-names></name></person-group><article-title>Autophagy in ischemic stroke</article-title><source>Prog Neurobiol</source><year>2018</year><volume>163</volume><fpage>98</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2018.01.001</pub-id><pub-id pub-id-type="pmid">29331396</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Sluimer</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>M</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name><name name-style="western"><surname>Pattison</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Macrophage autophagy plays a protective role in advanced atherosclerosis</article-title><source>Cell Metab</source><year>2012</year><volume>15</volume><issue>4</issue><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.01.022</pub-id><pub-id pub-id-type="pmid">22445600</pub-id><pub-id pub-id-type="pmcid">PMC3322248</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CJ</given-names></name></person-group><article-title>Astrocytes autophagy in aging and neurodegenerative disorders</article-title><source>Biomed Pharmacother</source><year>2020</year><volume>122</volume><fpage>109691</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109691</pub-id><pub-id pub-id-type="pmid">31786465</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roohbakhsh</surname><given-names>A</given-names></name><name name-style="western"><surname>Shamsizadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>AW</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>G</given-names></name></person-group><article-title>Melatonin as an endogenous regulator of diseases: the role of autophagy</article-title><source>Pharmacol Res</source><year>2018</year><volume>133</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.01.022</pub-id><pub-id pub-id-type="pmid">29408249</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carloni</surname><given-names>S</given-names></name><name name-style="western"><surname>Girelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Scopa</surname><given-names>C</given-names></name><name name-style="western"><surname>Buonocore</surname><given-names>G</given-names></name><name name-style="western"><surname>Longini</surname><given-names>M</given-names></name><name name-style="western"><surname>Balduini</surname><given-names>W</given-names></name></person-group><article-title>Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia</article-title><source>Autophagy</source><year>2010</year><volume>6</volume><issue>3</issue><fpage>366</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.4161/auto.6.3.11261</pub-id><pub-id pub-id-type="pmid">20168088</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Cui</surname><given-names>P</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microglial PGC-1&#945; protects against ischemic brain injury by suppressing neuroinflammation</article-title><source>Genome Med</source><year>2021</year><volume>13</volume><issue>1</issue><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00863-5</pub-id><pub-id pub-id-type="pmid">33771213</pub-id><pub-id pub-id-type="pmcid">PMC8004413</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name></person-group><article-title>Beta-elemene treatment is associated with improved outcomes of patients with esophageal squamous cell carcinoma</article-title><source>Surg Oncol</source><year>2017</year><volume>26</volume><issue>4</issue><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.suronc.2017.07.002</pub-id><pub-id pub-id-type="pmid">29113648</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>&#946;-elemene blocks lipid-induced inflammatory pathways via PPAR&#946; activation in heart failure</article-title><source>Eur J Pharmacol</source><year>2021</year><volume>910</volume><fpage>174450</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174450</pub-id><pub-id pub-id-type="pmid">34454927</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group><article-title>&#946;-elemene alleviates hyperglycemia-induced cardiac inflammation and remodeling by inhibiting the JAK/STAT3-NF-&#954;B pathway</article-title><source>Phytomedicine</source><year>2023</year><volume>119</volume><fpage>154987</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2023.154987</pub-id><pub-id pub-id-type="pmid">37531901</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Si</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jing</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Suppression of the RAC1/MLK3/p38 signaling pathway by &#946;-Elemene alleviates sepsis-associated encephalopathy in mice</article-title><source>Front Neurosci</source><year>2019</year><volume>13</volume><fpage>358</fpage><pub-id pub-id-type="doi">10.3389/fnins.2019.00358</pub-id><pub-id pub-id-type="pmid">31068775</pub-id><pub-id pub-id-type="pmcid">PMC6491839</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><etal/></person-group><article-title>&#946;-elemene inhibits radiation and hypoxia-induced macrophages infiltration via Prx-1/NF-&#954;B/HIF-1&#945; signaling pathway</article-title><source>Onco Targets Ther</source><year>2019</year><volume>12</volume><fpage>4203</fpage><lpage>4211</lpage><pub-id pub-id-type="doi">10.2147/OTT.S196910</pub-id><pub-id pub-id-type="pmid">31213838</pub-id><pub-id pub-id-type="pmcid">PMC6549424</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>F</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Integrating network pharmacology and bioinformatics to explore and experimentally verify the regulatory effect of Buyang Huanwu decoction on glycolysis and angiogenesis after cerebral infarction</article-title><source>J Ethnopharmacol</source><year>2024</year><volume>319</volume><issue>Pt 3</issue><fpage>117218</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2023.117218</pub-id><pub-id pub-id-type="pmid">37806535</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>XL</given-names></name><name name-style="western"><surname>Lu</surname><given-names>SS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MR</given-names></name><name name-style="western"><surname>Tang</surname><given-names>WD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>YR</given-names></name><etal/></person-group><article-title>Melatonin receptor agonist ramelteon attenuates mouse acute and chronic ischemic brain injury</article-title><source>Acta Pharmacol Sin</source><year>2020</year><volume>41</volume><issue>8</issue><fpage>1016</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0361-2</pub-id><pub-id pub-id-type="pmid">32107468</pub-id><pub-id pub-id-type="pmcid">PMC7470806</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Fr&#233;chou</surname><given-names>M</given-names></name><name name-style="western"><surname>Liere</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Pianos</surname><given-names>A</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>N</given-names></name><etal/></person-group><article-title>A role of endogenous progesterone in stroke cerebroprotection revealed by the neural-specific deletion of its intracellular receptors</article-title><source>J Neurosci</source><year>2017</year><volume>37</volume><issue>45</issue><fpage>10998</fpage><lpage>11020</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3874-16.2017</pub-id><pub-id pub-id-type="pmid">28986464</pub-id><pub-id pub-id-type="pmcid">PMC6596486</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Dynorphin activation of kappa opioid receptor promotes microglial polarization toward M2 phenotype via TLR4/NF-&#954;B pathway</article-title><source>Cell Biosci</source><year>2020</year><volume>10</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s13578-020-00387-2</pub-id><pub-id pub-id-type="pmid">32206297</pub-id><pub-id pub-id-type="pmcid">PMC7079364</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takano</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>&#946;-elemene regulates M1&#8211;M2 macrophage balance through the ERK/JNK/P38 MAPK signaling pathway</article-title><source>Commun Biol</source><year>2022</year><volume>5</volume><issue>1</issue><fpage>519</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-03369-x</pub-id><pub-id pub-id-type="pmid">35641589</pub-id><pub-id pub-id-type="pmcid">PMC9156783</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>E</given-names></name><name name-style="western"><surname>Ilyas</surname><given-names>G</given-names></name><name name-style="western"><surname>Lalazar</surname><given-names>G</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Haseeb</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1009787</pub-id><pub-id pub-id-type="pmid">25650776</pub-id><pub-id pub-id-type="pmcid">PMC4502775</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanjurjo</surname><given-names>L</given-names></name><name name-style="western"><surname>Aran</surname><given-names>G</given-names></name><name name-style="western"><surname>T&#233;llez</surname><given-names>&#201;</given-names></name><name name-style="western"><surname>Am&#233;zaga</surname><given-names>N</given-names></name><name name-style="western"><surname>Armengol</surname><given-names>C</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>D</given-names></name><etal/></person-group><article-title>CD5L promotes M2 macrophage polarization through autophagy-mediated upregulation of ID3</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>480</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00480</pub-id><pub-id pub-id-type="pmid">29593730</pub-id><pub-id pub-id-type="pmcid">PMC5858086</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lian</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Autophagy induced by hypoxia in pulpitis is mediated by HIF-1&#945;/BNIP3</article-title><source>Arch Oral Biol</source><year>2024</year><volume>159</volume><fpage>105881</fpage><pub-id pub-id-type="doi">10.1016/j.archoralbio.2024.105881</pub-id><pub-id pub-id-type="pmid">38199116</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>M</given-names></name><name name-style="western"><surname>Viollet</surname><given-names>B</given-names></name><name name-style="western"><surname>Guan</surname><given-names>KL</given-names></name></person-group><article-title>AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1</article-title><source>Nat Cell Biol</source><year>2011</year><volume>13</volume><issue>2</issue><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/ncb2152</pub-id><pub-id pub-id-type="pmid">21258367</pub-id><pub-id pub-id-type="pmcid">PMC3987946</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vergadi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ieronymaki</surname><given-names>E</given-names></name><name name-style="western"><surname>Lyroni</surname><given-names>K</given-names></name><name name-style="western"><surname>Vaporidi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsatsanis</surname><given-names>C</given-names></name></person-group><article-title>Akt signaling pathway in macrophage activation and M1/M2 polarization</article-title><source>J Immunol</source><year>2017</year><volume>198</volume><issue>3</issue><fpage>1006</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601515</pub-id><pub-id pub-id-type="pmid">28115590</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsivgoulis</surname><given-names>G</given-names></name><name name-style="western"><surname>Katsanos</surname><given-names>AH</given-names></name><name name-style="western"><surname>Sandset</surname><given-names>EC</given-names></name><name name-style="western"><surname>Turc</surname><given-names>G</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TN</given-names></name><name name-style="western"><surname>Bivard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Thrombolysis for acute ischaemic stroke: current status and future perspectives</article-title><source>Lancet Neurol</source><year>2023</year><volume>22</volume><issue>5</issue><fpage>418</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00519-1</pub-id><pub-id pub-id-type="pmid">36907201</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>EH</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>TP</given-names></name></person-group><article-title>Exciting, radical, suicidal: how brain cells die after stroke</article-title><source>Stroke</source><year>2005</year><volume>36</volume><issue>2</issue><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000153069.96296.fd</pub-id><pub-id pub-id-type="pmid">15637315</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tian</surname><given-names>DC</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Ducruet</surname><given-names>AF</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>MT</given-names></name><name name-style="western"><surname>Shi</surname><given-names>FD</given-names></name></person-group><article-title>Global brain inflammation in stroke</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><issue>11</issue><fpage>1058</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30078-X</pub-id><pub-id pub-id-type="pmid">31296369</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name></person-group><article-title>Review of the traditional uses, phytochemistry, and pharmacology of Curcuma wenyujin Y H Chen et C Ling</article-title><source>J Ethnopharmacol</source><year>2021</year><volume>269</volume><fpage>113689</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2020.113689</pub-id><pub-id pub-id-type="pmid">33309584</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Lan</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><etal/></person-group><article-title>An investigation of the JAZ Family and the CwMYC2-like protein to reveal their regulation roles in the MeJA-induced biosynthesis of &#946;-Elemene in curcuma wenyujin</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>19</issue><fpage>15004</fpage><pub-id pub-id-type="doi">10.3390/ijms241915004</pub-id><pub-id pub-id-type="pmid">37834452</pub-id><pub-id pub-id-type="pmcid">PMC10573570</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>XS</given-names></name><name name-style="western"><surname>Xie</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Huang-Fu</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ni</surname><given-names>LF</given-names></name><etal/></person-group><article-title>An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas</article-title><source>J Pharm Pharmacol</source><year>2009</year><volume>61</volume><issue>12</issue><fpage>1653</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1211/jpp.61.12.0010</pub-id><pub-id pub-id-type="pmid">19958588</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Su</surname><given-names>CY</given-names></name></person-group><article-title>Pharmacokinetics and disposition of beta-elemene in rats</article-title><source>Yao Xue Xue Bao</source><year>2000</year><volume>35</volume><issue>10</issue><fpage>725</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">11372435</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zou</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>&#946;-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway</article-title><source>Phytomedicine</source><year>2020</year><volume>69</volume><fpage>153184</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153184</pub-id><pub-id pub-id-type="pmid">32199253</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Shao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Fan</surname><given-names>XX</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name><etal/></person-group><article-title>&#946;-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer</article-title><source>Pharmacol Res</source><year>2023</year><volume>191</volume><fpage>106739</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106739</pub-id><pub-id pub-id-type="pmid">36948327</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Combinative treatment of &#946;-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>11</issue><fpage>5107</fpage><lpage>5119</lpage><pub-id pub-id-type="doi">10.7150/thno.44705</pub-id><pub-id pub-id-type="pmid">32308771</pub-id><pub-id pub-id-type="pmcid">PMC7163451</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takano</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wakatsuki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intestinal regulatory T cell induction by &#946;-elemene alleviates the formation of fat tissue-related inflammation</article-title><source>iScience</source><year>2021</year><volume>24</volume><issue>1</issue><fpage>101883</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101883</pub-id><pub-id pub-id-type="pmid">33364577</pub-id><pub-id pub-id-type="pmcid">PMC7750371</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis</article-title><source>Acta Pharm Sin B</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>708</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.11.002</pub-id><pub-id pub-id-type="pmid">33777677</pub-id><pub-id pub-id-type="pmcid">PMC7982432</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lim</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>SI</given-names></name><name name-style="western"><surname>Kang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Park</surname><given-names>EM</given-names></name></person-group><article-title>Noggin improves ischemic brain tissue repair and promotes alternative activation of microglia in mice</article-title><source>Brain Behav Immun</source><year>2014</year><volume>40</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2014.03.013</pub-id><pub-id pub-id-type="pmid">24704569</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Ye</surname><given-names>QB</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Modulating the polarization phenotype of microglia&#8212;a valuable strategy for central nervous system diseases</article-title><source>Ageing Res Rev</source><year>2024</year><volume>93</volume><fpage>102160</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2023.102160</pub-id><pub-id pub-id-type="pmid">38065225</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>In situ Engineering of Tumor-Associated macrophages via a nanodrug-delivering-drug (&#946;-Elemene@Stanene) strategy for enhanced cancer chemo-immunotherapy</article-title><source>Angew Chem Int Ed Engl</source><year>2023</year><volume>62</volume><issue>41</issue><fpage>e202308413</fpage><pub-id pub-id-type="doi">10.1002/anie.202308413</pub-id><pub-id pub-id-type="pmid">37380606</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>S</given-names></name><name name-style="western"><surname>Muthuraman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Meenu</surname><given-names>M</given-names></name><name name-style="western"><surname>Priya</surname><given-names>P</given-names></name><name name-style="western"><surname>Pemaiah</surname><given-names>B</given-names></name></person-group><article-title>Anti-inflammatory effects of royal poinciana through inhibition of toll-like receptor 4 signaling pathway</article-title><source>Int Immunopharmacol</source><year>2016</year><volume>34</volume><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2016.02.027</pub-id><pub-id pub-id-type="pmid">26971223</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Mani</surname><given-names>R</given-names></name><name name-style="western"><surname>Pugazhendhi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shanmuganathan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cytotoxic effects of a sesquiterpene &#946;-elemene on THP-1 leukemia cells is mediated via crosstalk between beclin-1 mediated autophagy and caspase-dependent apoptosis</article-title><source>Process Biochem</source><year>2019</year><volume>87</volume><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.procbio.2019.09.006</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Geniposide inhibits NLRP3 inflammasome activation via autophagy in BV-2 microglial cells exposed to oxygen-glucose deprivation/reoxygenation</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>84</volume><fpage>106547</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106547</pub-id><pub-id pub-id-type="pmid">32361652</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery</article-title><source>Autophagy</source><year>2021</year><volume>17</volume><issue>10</issue><fpage>2905</fpage><lpage>2922</lpage><pub-id pub-id-type="doi">10.1080/15548627.2020.1847799</pub-id><pub-id pub-id-type="pmid">33317392</pub-id><pub-id pub-id-type="pmcid">PMC8525999</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>